Academic Paper

Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing

September, 2021

In brief:

Xu et. al developed a miniature CRISPR system for genome engineering via protein and guide RNA engineering. Whereas the natural Cas12f does not function in mammalian cells, engineered Cas12f mutants, named CasMINI, show comparable activities with Cas12a for efficient gene activation. CasMINI also enables robust gene editing and base editing.

Highlights

Single Cortical Neurons as Deep Artificial Neural Networks

September, 2021

Highlights

• Cortical neurons are well approximated by a deep neural network (DNN) with 5–8 layers

• DNN’s depth arises from the interaction between NMDA receptors and dendritic morphology

• Dendritic branches can be conceptualized as a set of spatiotemporal pattern detectors

• We provide a unified method to assess the computational complexity of any neuron type

Summary

Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections

August, 2021

Abstract

Background: Reports of waning vaccine-induced immunity against COVID-19 have begun to surface. With that, the comparable long-term protection conferred by previous infection with SARS-CoV-2 remains unclear.

The Economic Effect of the COVID-19 Lockdown in the United States: Was the Cure Worse than the Disease?

May, 2021

Abstract

COVID-19 is an ongoing global outbreak of coronavirus disease 2019, an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern on January 30, 2020; and a pandemic on March 11, 2020.

Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines

August, 2021

Abstract

Background: 

Repurposed medicines may have a role against the SARS-CoV-2 virus. The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested in numerous clinical trials.

Areas of uncertainty: 

We assessed the efficacy of ivermectin treatment in reducing mortality, in secondary outcomes, and in chemoprophylaxis, among people with, or at high risk of, COVID-19 infection.

Data sources: 

Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination?

August, 2021

Highlights

  • Infection-enhancing antibodies have been detected in symptomatic Covid-19
  • Antibody dependent enhancement (ADE) is a potential concern for vaccines
  • Enhancing antibodies recognize both the Wuhan strain and Delta variants
  • ADE of Delta variants is a potential risk for current vaccines
  • Vaccine formulations lacking ADE epitope are suggested

Abstract

Pages